We found that a crude extract from Salvia officinalis (sage) reduced the minimum inhibitory concentrations (MICs) of aminoglycosides in vancomycin-resistant enterococci (VRE). We isolated the effective compound from the extract and identified it as carnosol, one of diterpenoids. Carnosol showed a weak antimicrobial activity, and greatly reduced the MICs of various aminoglycosides (potentiated the antimicrobial activity of aminoglycosides) and some other types of antimicrobial agents in VRE. Carnosic acid, a related compound, showed the similar activity. The effect of carnosol and carnosic acid with gentamicin was synergistic.
The infections caused by vancomycin-resistant enterococci (VRE) are very serious problems because of the resistance against not only vancomycin but also many types of antimicrobials. Although enterococci are less virulent, they cause nosocomial infections. VRE was noted from the U.K. and France at first, and then they have become one of the most important nosocomial pathogens worldwide. 1) In the case of the United States, the percentage of VRE in enterococci isolated at intensive care units (ICUs) was 0.4% in 1989, but it was raised up to 28.5% in 2003. 2, 3) Of the strains belonging to the enterococcal species, Enterococcus faecalis and E. faecium are common isolates from human. 4) Among the clinical isolates of enterococcal species, E. faecalis accounts for 80-90% and the rest is mainly E. faecium.
5) The strains of VRE are mainly E. faecalis and E. faecium. In the case of the treatment for infections caused by enterococci, it is one of the most popular methods to use aminoglycosides together with inhibitors of cell wall synthesis such as b-lactams although enterococci are intrinsically resistant to aminoglycosides. 6, 7) Nonetheless, in the cases of infection by highly resistant enterococci against aminoglycosides (for example, MIC of gentamicin is equal or more than 500 mg/ml, or MIC of streptomycin is equal or more than 2000 mg/ml), 6, 7) use of this treatment is limited and it is very difficult to treat patients in such cases. Because many strains of enterococci, methicillin-resistant Staphylococcus aureus (MRSA) and others are resistant against many antimicrobial agents, it is urgently necessary to develop new drugs or new methods effective on such multidrug resistant bacteria.
We have been trying to discover inhibitors of drug resistance systems in bacteria. Inhibitors of drug resistance mechanisms seem to be valuable, because they should make resistant bacteria sensitive to drugs. Until now, we and other groups have reported many compounds that potentiated activity of antimicrobial agents against drug-resistant bacteria. For example, corilagin, 8, 9) tellimagrandin I, 9,10) epicatechin gallate, 11) epigallocatechin gallate 12) or many flavonoids 13) potentiated antibacterial activity of b-lactams against methicillin-resistant Staphylococcus aureus (MRSA). Baicalein potentiated activities of tetracycline and b-lactams against MRSA, 14) 5Ј-methoxyhydonocarpin inhibited NorA pump in S. aureus 15) and MC-207,110 (phenylalanine arginine bnaphthylamide, PAbN) and its relatives potentiated some types of antimicrobials that are substrates of one of multidrug efflux pumps, MexAB-OprM of Pseudomonas aeruginosa [16] [17] [18] [19] [20] [21] or AcrAB-TolC of Escherichia coli 22) and Enterobacter aerogenes. 23) Regarding to VRE, allicin, which potentiated activity of vancomycin against VRE, 24) and [10] gingerol and some detergents, such as sodium dodecyl sulfate (SDS) and Triton X-100, which potentiated some antimicrobials including aminoglycosides against enterococci 25) have been reported. During the course of our studies, we found that a crude extract from sage leaves reduced the MICs of aminoglycosides (potentiated the antimicrobial activity of aminoglycosides) against VRE. We isolated the effective compound and identified it as carnosol.
MATERIALS AND METHODS
Bacterial Strains Four VRE strains, E. faecium FN-1, E. faecium BM4147, E. faecalis NCTC 12201, E. faecalis FA2-2, and Serratia marcescens NUSM8905 were kindly provided by Dr. Y. Ike (Gunma University) and Dr. Y. Arakawa (National Institute of Infectious Diseases, Tokyo), respectively. MRSA OM481 and OM584 were clinically isolated in Okayama University hospital. P. aeruginosa PAO1 was also used in this study.
Drug Susceptibility Testing The MICs of antimicrobial agents with VRE, MRSA, S. marcescens or P. aeruginosa were determined in cation-supplemented Mueller-Hinton broth (CSMHB), Mueller-Hinton broth (Difco Laboratories) supplemented with CaCl 2 (50 mg/ml) and MgSO 4 (25 mg/ml), by a microdilution method.
5)

Isolation of Effective Compounds
To isolate the compound that showed the highest effect on the reduction of the MIC of aminoglycoside against VRE, 850 g of dried, ground leaves of Salvia officinalis were extracted with 8 l of 70% acetone at room temperature and filtered. The extract was concentrated and dried by using a rotary evaporator, and 300 g of sample was obtained. A half of the sample was dissolved with water and extracted with ethyl acetate (AcOEt). The AcOEt extract was concentrated by using the rotary evaporator and dried by using N 2 gas and 70 g of sample was obtained. This AcOEt extract was subjected to column chromatography over DIAION HP-20 (Mitsubishi-Kagaku Co.) and eluted with aqueous methanol (70, 80, 90, 100%) in a stepwise manner. At the final step, it was eluted with 100% acetone. The fraction eluted with 90% methanol showed the highest activity to reduce the MIC of arbekacin against VRE strains, E. faecium FN-1 and E. faecalis FA2-2. One gram of this 90% methanol fraction was further subjected to chromatography over Sephadex LH-20 (Amersham Biosciences Co.) by using 100% ethanol as a solvent. Active fractions were collected and 200 mg of the dried material from these fractions were separated by preparative high-pressure liquid chromatography (HPLC) on Inertsil ODS-3 (2 by 25 cm, GL science Co.) using 70% acetonitrile as an eluant. After that, active fraction was purified by HPLC on Inertsil ODS-3 (1 by 25 cm, GL science Co.) using 60% acetonitrile as an eluant. Twenty milligrams of the active compound was isolated and its structure was determined by 1 H-, 13 C-NMR and MS spectrum.
Materials The leaves of S. officinalis, carnosic acid, antimicrobial agents and chemicals used in this study were purchased from commercial sources. Arbekacin was obtained from Meiji Seika Co. (Tokyo, Japan).
RESULTS AND DISCUSSION
Isolation and Identification of the Effective Compound
We have been trying to find compounds that potentiate activity of antimicrobial agents against VRE and other multidrug resistant bacteria. We found that the extract from sage leaves showed such effect, and greatly reduced MICs of aminoglycosides in VRE. In the presence of 1/8 MIC of 70% acetone extract from sage, the MIC of arbekacin was reduced to 1/32 in VRE. The AcOEt extract of 70% acetone extract showed the highest activity, and the presence of 1/8 MIC of this fraction reduced the MIC of arbekacin to 1/16. Then, AcOEt extract was subjected to column chromatography over DI-AION HP-20. The 90% methanol fraction that showed the highest activity was further subjected to chromatography over Sephadex LH-20 by using 100% ethanol as a solvent. Addition of 1/8 MIC of the most effective fraction reduced the MIC of arbekacin to 1/8. This fraction was subjected to HPLC and we isolated an effective compound, and identified it as carnosol, one of diterpenoids. It is likely that other compound(s) that show additive effect on the reduction of MIC of arbekacin is (are) present in the 70% acetone extract because the magnitude of reduction of the MIC gradually decreased during purification of carnosol. Since a structurally related compound carnosic acid was commercially available, we also tested the effect of carnosic acid. The structures of carnosol and carnosic acid are shown in Fig. 1 . Carnosol and carnosic acid showed weak antimicrobial activity on grampositive bacteria (E. faecium, E. faecalis, S. aureus: MICs were 32-64 mg/ml) but not on gram-negative ones (P. aeruginosa, S. marcescens: MICs were >128 mg/ml) ( Table   1 ). The MIC values regarding S. aureus were almost same as those reported by other group. 26) It should be noted that other activities of carnosol and carnosic acid, for example inhibition of pancreatic lipase activity, 27) antioxidant activity 28) and anti-inflammatory activity, 29) have been reported. Effects of Carnosol and Carnosic Acid on VRE When carnosol (16 mg/ml) or carnosic acid (8 mg/ml) was added to the growth medium, the MICs of several aminoglycosides for VRE were greatly reduced compared with MICs measured in the absence of these compounds ( Table 2) . Concentrations of carnosol and carnosic acid added to the medium were lower than 1/4 of their MICs. These two compounds reduced the MIC values of almost all aminoglycosides tested about 8-to 128-fold, or more. Thus, carnosol and carnosic acid greatly potentiated the antimicrobial activity of aminoglycosides on VRE. The FIC index was calculated for the enhanced antibacterial effect of arbekacin by carnosol or carnosic acid. The FIC index for arbekacin in combination with carnosol or carnosic acid ranged from 0.19 to 0.38 in the enterococcal strains. These results indicate that the antibacterial effect of arbekacin plus carnosol or carnosic acid is synergistic. They also potentiated activity of other antimicrobial agents, such as ethidium bromide, erythromycin and tetracycline, on some VRE strains (Table 2 ). However they did not affect the activities of b-lactam (ampicillin) or fluoroquinolone (norfloxacin) (data not shown).
Effects of Carnosol and Carnosic Acid on Other DrugResistant Bacteria
We also examined the effects of carnosol and carnosic acid on the activity of aminoglycosides on MRSA, P. aeruginosa and S. marcescens. Carnosol and carnosic acid potentiated the antimicrobial activity of aminoglycosides on MRSA although their activity was weaker than that observed with VRE (Tables 2, 3 ). We also found that antimicrobial activity of ethidium bromide on MRSA was potentiated by carnosol or carnosic acid ( the activity of tetraclycline and erythromycin against S. aureus. 26 ) However, we observed only a small effect with tetracycline (Table 3) . Since MRSA strains used in our study showed high resistance level regarding erythromycin, perhaps we could not detect the effect of carnosol or carnosic acid on the MIC of erythromycin in these cells. Thus, their potetiation activities with tetracycline and erythromycin might be specific to some strains of S. aureus. Carnosol and carnosic acid were ineffective on P. aeruginosa and S. marcescens (data not shown), thus, it seems that these compounds are not effective on gram-negative bacteria. Although the effects of carnosol and carnosic acid are not so specific to VRE, their antimicrobial spectrum seems to be narrow.
Possible Mechanism of Action There are several mechanisms that confer aminoglycosides-resistance to enterococci. Carnosol and carnosic acid are thought to inhibit one or some of these mechanisms. The first mechanism of the resistance is related to aminoglycoside-modifying enzymes. To investigate the effect of carnosol or carnosic acid on these enzymes, we used two types of VRE strains. One type is E. faecium FN-1 and E. faecalis NCTC12201, they possess at least 2 aminoglycoside-modifying enzymes, AAC(6Ј)/ APH(2Љ) and APH(3Ј). Another type is E. faecium BM4147 and E. faecalis FA2-2, they do not possess these enzymes. If carnosol and carnosic acid inhibit these modification enzymes, AAC(6Ј)/APH(2Љ) and/or APH(3Ј), they should not affect the MICs of aminoglycosides with E. faecium BM4147 and E. faecalis FA2-2 that do not possess these modification enzymes. However, as shown in Table 2 , carnosol and carnosic acid greatly reduced the MICs of aminoglycosides with all of the four strains. These results suggest that the effect of carnosol and carnosic acid on antimicrobial activity of aminoglycosides is not related to aminoglycoside-modifying enzymes, at least AAC(6Ј)/ APH(2Љ) and APH(3Ј). The second mechanism is the low aminoglycoside permeation into enterococcal cells. It is known that enterococci are relatively impermeable to aminoglycosides.
30) It seems possible that carnosol or carnosic acid affects (increases) cell membrane permeability and then aminoglycosides can easily enter into the cells in the presence of carnosol or carnosic acid. Carnosol and carnosic acid potentiated antimicrobial activity not only of aminoglycosides but also of other antimicrobials such as ethidium bromide, erythromycin and tetracycline (Table 2 ). In MRSA, these compounds also reduced MICs of aminoglycosides. These results support the view that carnosol and carnosic a) The concentrations added to the medium are lower than 1/4 of their MICs (carnosol, 16 mg/ml; or carnosic acid, 8 mg/ml).
acid increase permeability of cell membrane in gram-positive bacteria. It is likely that presence of outer membrane in gram-negative bacteria hinders permeation of aminoglycosides and others into cells. The third possible mechanism is the involvement of drug efflux pumps. The mechanism for resistance against ethidium seems to be due to the efflux pumps. EfrAB, a multidrug efflux pump in E. faecalis, could be related to resistance against many drugs such as arbekacin, ciprofloxacin, doxycycline and ethidium bromide. 31) Thus, it seems also possible that carnosol and carnosic acid inhibit such drug efflux pump(s). We do not have experimental data for or against this possibility at the present time.
Antimicrobial drugs effective for treatment of patients infected with VRE or MRSA are limited. Aminoglycosides are one of the important antimicrobials for the treatment of such patients. Thus, it is important and valuable to find compounds that potentiate antimicrobial activity of aminoglycosides on VRE and MRSA. Carnosol and carnosic acid could be candidates or lead compounds for such type of drugs.
